Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
NCT03364400
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
116
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
VT1021
Sponsor
Vigeo Therapeutics, Inc.